5 Stocks That Mattered on Day 1 of ASCO 2026

ASCO is one of the most important events on the biotech calendar, but not every presentation captures investors' attention equally.

Day 1 featured dozens of clinical updates across oncology, yet a handful of companies stood out because of the technologies they are advancing, the markets they are targeting, and the potential impact on future valuations.

Here are five tickers that mattered on Day 1 of ASCO 2026.

NUVL: Building a Potential Next-Generation ALK Franchise

Nuvalent presented updated data from ALKOVE-1 evaluating neladalkib in ALK-positive non-small cell lung cancer.

What makes this asset important is not simply its response rate. Neladalkib continues to demonstrate activity in heavily pretreated patients, including those with CNS disease and resistance mutations such as G1202R. Early first-line data also remain impressive, with an ORR of 86%.

The ALK market has long been one of the most attractive targeted oncology opportunities. As investors look beyond current standards of care, neladalkib continues to strengthen its position as one of the most closely watched next-generation ALK programs.

Stock move: +1.0%

LLY: Can Lilly Build a Best-in-Class Nectin-4 ADC?

Eli Lilly presented initial results from NEXUS-01 evaluating LY4052031, a Nectin-4-targeted antibody-drug conjugate in advanced or metastatic urothelial carcinoma.

The data showed meaningful activity, including responses in patients previously treated with Padcev. Yet the presentation raised an important question for investors: can LY4052031 meaningfully differentiate itself in an increasingly crowded Nectin-4 landscape?

The opportunity is significant. Nectin-4 has already been clinically validated, but future winners may be determined by efficacy, durability, safety, and sequencing advantages rather than target selection alone.

Stock move: -2.0%

CRBP: One of Day 1's Biggest Small-Cap Winners

Corbus Pharmaceuticals reported encouraging data for CRB-701, a next-generation Nectin-4 ADC, in recurrent or metastatic cervical cancer.

The study demonstrated an unconfirmed ORR of up to 37.5% at higher dose levels alongside a manageable safety profile. While still early, the presentation attracted investor attention as CRB-701 continues to expand the Nectin-4 opportunity beyond urothelial cancer. Among companies presenting on Day 1, Corbus generated one of the strongest stock reactions.

Stock move: +3.5%

REGN: Bispecific Competition Continues to Intensify

Regeneron presented first-line data from OLYMPIA-3 evaluating odronextamab plus CHOP in high-risk DLBCL.

The results were encouraging, with complete response rates reaching 85% and the company selecting a regimen for advancement into Phase 3 development.

What makes this story important is the broader competitive landscape. Bispecific antibodies continue to reshape lymphoma treatment, and investors are increasingly focused on which programs can establish durable differentiation as more assets move toward earlier treatment settings.

Stock move: -1.1%

BMY: CELMoDs Continue Moving Up the Treatment Paradigm

Bristol Myers Squibb delivered two important hematology updates during Day 1.

Golcadomide showed encouraging efficacy in newly diagnosed aggressive B-cell lymphoma, while mezigdomide met its primary endpoint in the Phase 3 SUCCESSOR-2 study in relapsed/refractory multiple myeloma.

Taken together, these datasets reinforce the strategic importance of the CELMoD platform. More importantly, they demonstrate Bristol Myers Squibb's continued effort to move these assets into larger and earlier treatment settings.

Stock move: +0.5%

What These Five Tickers Tell Us About ASCO Day 1

Several themes emerged from these presentations:

• ADC competition remains one of the most important battles in oncology.

• Precision oncology continues to reward companies that can overcome resistance mechanisms.

• Bispecific antibodies are expanding into earlier lines of therapy.

• Investors are increasingly evaluating differentiation rather than simply positive clinical results.

Perhaps the most important lesson from Day 1 is that good data alone is no longer enough.

In today's oncology market, investors want to see evidence that an asset can capture meaningful market share, establish a competitive advantage, and create long-term value beyond the next headline.

ASCO 2026 is just beginning, but these five tickers gave investors plenty to watch.

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 05/29/26 MD, RF